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Introduction: Although subcutaneous xenograft models have been 
widely used to evaluate the antitumor activity of new compounds, 
these models present a major disadvantage because the tumors do 
not accurately represent the cancer biology, especially with regard 
to metastasis and drug sensitivity. Effective murine models of small-
cell lung cancer (SCLC) are needed.
Methods: To provide strategies for studying new therapies and tumor 
biology, we developed three orthotopic models of human SCLC 
(H69A, a variant of the National Cancer Institute [NCI]-H69 cell 
line selected for invasiveness in vitro, NCI-H187, and NCI-N417) 
in nude mice. Tumor cells were injected into their lungs and new 
cell lines were established from these tumors (H69ALu, H187Lu, 
and N417Lu) to select for a reproducible tumor growth pattern and 
minimize variations in tumor size.
Results: In all three models tumors started as a solitary mass in the 
left lung and spread to mediastinal and axillary lymph nodes and to 
the right lung in a pattern similar to that observed in human SCLC. 
To test the accuracy of this model in representing SCLC as seen in 
the clinic, we compared the efficacy of chemotherapeutic agents in 
each model. Irinotecan significantly inhibited the growth and pro-
gression of all three human SCLC tumors, and cisplatin, paclitaxel, 
and etoposide significantly inhibited the growth and progression of 
H69ALu tumors over the control agent.
Conclusions: We have established three orthotopic murine models 
of human SCLC closely resembling the course of human SCLC 
seen in the clinic including metastasis to lymph nodes and distant 
organs. They provide a means for better understanding the biology 
of this disease and will enable evaluation of novel therapeutic 
strategies.
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Small-cell lung cancer (SCLC) accounts for approximately 13% of all cases of lung cancer diagnosed in the United 
States.1 These tumors are characterized by rapid growth and 
good response to first-line chemotherapy or radiation. Because 
of the high propensity of early dissemination, approximately 
two thirds of patients present with extensive disease which 
is defined as involvement beyond the radiation port. Despite 
initial response to therapy, the majority of patients die of the 
disease, with cure rates among those with disease limited to 
one hemithorax of ranging from 9% in stage IIIB to 38% in 
stage IA, whereas the presence of distant metastases implies 
an essentially incurable disease.2
The standard therapy for patients with SCLC has 
been the combination of cisplatin and etoposide, either as 
a single modality for patients with metastatic disease or in 
combination with radiation therapy in patients with limited 
disease.3 Although the combination of cisplatin and irinotecan 
was associated with a significant improvement in survival 
compared with cisplatin plus etoposide in the Japan Clinical 
Oncology Group study 9511,4 subsequent studies in the 
United states did not confirm this benefit, with similar survival 
in the treatment arms.5,6 Topotecan is the standard second-line 
therapy7 whereas irinotecan,8 paclitaxel,9 and other agents can 
be used as alternatives.
Progress in the treatment of SCLC has been slow. The 
standard combination of cisplatin and etoposide has been 
used for the last three decades.10 As a result, the median sur-
vival for patients with extensive disease in the Surveillance, 
Epidemiology, and End Results database improved from 6.5 
months in 1973–1974 to 8.2 months in 1993–1994, probably 
reflecting the change in therapy from first-generation cyclo-
phosphamide and doxorubicin-based regimens to the second-
generation cisplatin and etoposide.11 To further support this 
hypothesis, a more recent study evaluating 68,611 patients with 
SCLC from the National Cancer Database showed no significant 
improvement in the survival from 1992 to 2007.12 Therefore, 
new therapeutic approaches for SCLC are urgently needed.
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The task of achieving survival improvement in patients 
with SCLC requires a better understanding of tumor biology, 
ideally through animal orthotopic models, which allows a 
better understanding of the tumor behavior in vivo. Although 
we developed a reliable, reproducible, and simple orthotopic 
model for human lung cancer from one human SCLC cell line 
using nude mice, as detailed previously,13 multiple models 
with different biological and clinical phenotypes may allow 
a better understanding of the behavior and treatment effects.
The objectives of our study were to establish a reliable, 
reproducible, simple, orthotopic murine model of SCLC; to 
characterize the biological status of the orthotopic and meta-
static lung tumors in this model and, to test the efficacy of 
cytotoxic agents in this model to validate it as an orthotopic 
model of SCLC suitable for testing molecularly targeted 
drugs.
MATERIALS AND METHODS
Cell Lines and Tissue Culture Conditions
Three human SCLC cell lines were studied. National 
Cancer Institute (NCI)-H187 and NCI-N417 were obtained 
from the (American Type Culture Collection, Manassas, VA), 
and NCI-H69A was established from human SCLC cell line 
NCI-H69 American Type Culture Collection in vitro using 
agarose to increase invasive properties in vivo, as described 
previously.13 Floating aggregates of these cell lines were cul-
tured in Roswell Park Memorial Institute 1640 supplemented 
with 10% fetal bovine serum, L-glutamine, and penicillin-
streptomycin. Cell cultures were incubated at 37°C in 5% car-
bon dioxide and 95% air. All the tumor cell cultures were free 
of Mycoplasma as well as the following pathogenic murine 
viruses: retrovirus type 3; pneumonia virus; K virus; Theiler’s 
encephalitis virus; Sendai virus; minute virus; mouse adeno-
virus; mouse hepatitis virus; lymphocytic choriomeningitis 
virus; ectromelia virus; and lactate dehydrogenase virus (as 
assayed by Microbiological Associates, Bethesda, MD).
Reagents
Cisplatin, irinotecan, paclitaxel, and etoposide were 
purchased from The University of Texas M.D. Anderson 
Cancer Center pharmacy. SN-38, an active metabolite of iri-
notecan, was kindly provided by Daiichi Pharmaceutical Co. 
Ltd. (Tokyo, Japan) and was used instead of irinotecan in all 
in vitro studies.
Animals and Animal Care
Male athymic nude mice were purchased from the 
Animal Production Area of the NCI Frederick Cancer 
Research and Development Center (Frederick, MD). The mice 
were housed and maintained in specific pathogen-free condi-
tions in facilities approved by the American Association for the 
Accreditation of Laboratory Animal Care in accordance with 
all current regulations and standards of the U.S. Department of 
Agriculture, U.S. Department of Health and Human Services, 
and the National Institutes of Health. When the mice were 8 to 
10 weeks old, they were used in accordance with institutional 
guidelines. All animal studies were conducted according to a 
protocol approved by the Institutional Animal Care and Use 
Committee.
Intrapulmonary Injection
Mice anesthetized with sodium pentobarbital (50 mg/kg) 
were placed in the right lateral decubitus position. A small skin 
incision to the left chest wall was made approximately 5 mm to the 
tail side of the scapula. The cell suspensions for injection into the 
lung were prepared with equal volumes of tumor cells (1.5 × 106) 
in Hanks’ balanced salt solution (HBSS; Sigma Checmicals 
Co., St. Louis, MO) and 0.5 mg/ml solution of growth factor-
reduced Matrigel.13 One-milliliter tuberculin syringes (Becton, 
Dickinson & Co., San Jose, CA) with 30-gauge hypodermic 
needles were used to inject the cells (75 μl) into the left lung. 
The needle was quickly advanced 5 to 7 mm into the thorax and 
quickly removed after the injection of the cell suspension. The 
skin was closed in a single layer using metallic clips (Autoclip; 
Clay Adams, Parsippany, NJ), which were removed on day 14 
after the operation. After tumor injection, the mice were turned 
to the left lateral decubitus position. Animals were observed for 
45 to 60 minutes until they fully recovered.
In Vivo Selection of Orthotopically 
Growing Cell Lines and Evaluation 
of Tumor Growth Properties
The intrapulmonary injection technique described 
above was used to inject NCI-N417, NCI-H187, and NCI-
H69A cells into the lungs of 10 nude mice. The mice were 
killed by an overdose of sodium pentobarbital when moribund, 
and the largest thoracic tumors were harvested using aseptic 
techniques, dissociated mechanically using a pipette, placed 
into culture for three to five passages in RPMI1640, and 
designated as cell lines N417Lu, H187Lu, and H69Alu. 
These cell lines were then injected into the lungs of a different 
group of 20 nude mice to compare the tumors growing 
orthotopically. To evaluate local tumor growth and metastasis, 
three to five mice transplanted with N417Lu and H187Lu 
cells were sacrificed on days 10, 20, 30, 40, and 50 and 3 to 5 
mice transplanted with H69Alu cells were killed on days 30, 
50, 90, and 120 after intrapulmonary injection.
Green Fluorescent Protein Transfection
For green fluorescent protein (GFP) transfection, cul-
tures of N417Lu and H187Lu cells were transfected with 
PEGFPC1 plasmid (Clontech Laboratories Inc., Palo Alto, 
CA) using FuGene VI transfection reagents (Roche Molecular 
Biochemicals, Indianapolis, IN) according to the manufac-
turer’s protocol. After 48 hours, the cells were harvested and 
plated at a ratio of 1:15 into selective medium containing 500 
to 800 µg/ml G418 (Life Technologies Inc., Gaithersburg, 
MD). Neomycin-resistant clones were isolated with cloning 
cylinders using trypsin-ethylenediamine- tetraacetic acid. For 
in vivo studies, stable clones with high-intensity GFP fluores-
cence were pooled together (N417Lu-GFP and H187Lu-GFP. 
We injected 1.5 × 106 N417Lu-GFP or H187Lu-GFP cells sus-
pended in Matrigel and Hanks’ balanced salt solution into the 
left lungs of six mice for each cell line. Three mice from each 
group were killed on day 15 and the other three mice on day 50.
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Growth-Inhibition Assay
To measure the antitumor activity of cisplatin, irinotecan, 
paclitaxel, and etoposide against the SCLC cell lines in vitro, a 
chemosensitivity test was performed using the (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The tetra-
zolium dye was purchased from Sigma Chemical Co (St. Louis, 
MO). Cells were seeded into 96-well microtiter plates at a den-
sity of 5 × 103 cells/well, and each drug was added at the various 
concentrations studied. After incubation for 72 hours at 37°C, 20 
μl of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide solution (5 mg/ml in phosphate-buffered saline) was added 
to each well and the plates were incubated for a further 4 hours 
at 37°C. After the plates were centrifuged at 200 g for 5 min-
utes, the medium was aspirated from each well, and 180 μl of 
dimethyl sulfoxide was added to each well to dissolve the forma-
zan. Optical density was measured at 570 nm using a 96-well 
Dynatech Microplate Reader Model MR 5000 (Chantilly, VA) 
and DeltaSoft Enzyme-Link ImmunoSorbent Assay analysis 
program (Biometallics, Princeton, NJ). Each experiment was 
performed in six replicate wells for each drug concentration and 
carried out independently three or four times. The half maximal 
inhibitory concentration (IC
50
) value was defined as the concen-
tration needed for a 50% reduction in the absorbance calculated 
based on the survival curves. Percent survival was calculated 
as follows: (mean absorbance of six replicate wells containing 
drugs–mean absorbance of six replicate background wells)/
(mean absorbance of six replicate drug-free wells–mean absor-
bance of six replicate background wells) × 100.
In Vivo Mouse Therapeutic Studies
Study 1
Human SCLC cells (N417Lu, H187Lu, and H69ALu) 
were grown in culture and 1.5 × 106 cells suspended in HBSS 
and Matrigel were injected into the lungs of nude mice. Ten 
days after the intrapulmonary injections were performed, 
three mice were killed, and the injected left lungs were exam-
ined histologically to identify actively growing cancer cells. 
Fifteen days after the intrapulmonary injections, the remain-
ing mice were randomly assigned to receive one of the fol-
lowing five treatments (five mice in each treatment group) for 
6 weeks: (1) one intraperitoneal injection per week of 200 μl 
HBSS (control group); (2) one intraperitoneal injection per 
week of irinotecan at 25 mg/kg (total dosage, 150 mg/kg); (3) 
one intraperitoneal injection per week of paclitaxel at 10 mg/
kg (total dosage, 60 mg/kg); (4) one intraperitoneal injection 
per week of cisplatin at 1.2 mg/kg (total dosage, 7.2 mg/kg); 
and (5) one intraperitoneal injection per week of etoposide 
at 8 mg/kg (total dosage, 48 mg/kg). The mice were weighed 
weekly to evaluate for drug treatment–associated weight loss 
and all animals were humanely killed after 6 weeks. This 
experiment was repeated once.
Study 2
Human SCLC cell lines (N417Lu) were injected into the 
lungs of nude mice as described before. Fifteen days after the 
intrapulmonary injections, the mice were randomly assigned 
to receive one of the following two treatments (eight mice in 
each treatment group): (1) one intraperitoneal injection per 
week of 200 μl HBSS (control group) or (2) one intraperito-
neal injection per week of irinotecan at 25 mg/kg for 6 weeks 
(total dosage; 150 mg/kg). The mice were then examined daily 
for evidence of tumor development. The mice were humanely 
killed when they became moribund.
Necropsy and Tissue Preparation
Mice were killed with a lethal dose of sodium pentobar-
bital (100 mg/kg). The thoracic organs were removed en bloc, 
including all lymph nodes and tumors. After dissection and 
removal of the heart, the lung and tumor mass were washed 
in cold PBS and weighed. Tumor volume was measured using 
the formula π/6 × largest diameter × (smallest diameter).2 
The other visceral organs were removed and inspected for the 
presence of metastases. Subcutaneous tumors were removed, 
washed in PBS, and weighed. For hemotoxylin and eosin 
staining procedures, one part of the tumor was fixed in forma-
lin and embedded in paraffin.
Microscopy and Imaging
For studies of tumor cells transfected with GFP, a Leica 
MZ FLIII fluorescence dissecting stereomicroscope (Leica 
Microsystems Inc., Bannockburn, IL) was used to visualize 
metastases fluorescently. The microscope was equipped with a 
100-W mercury vapor lamp power source and fitted with a GFP 
filter set. Images were processed using Image-Pro Plus (ver-
sion 4.0; Media Cybernetics LP, Silver Spring, MD) and Adobe 
Photoshop (version 5.5; Adobe Systems Inc., San Jose, CA).
Statistical Analysis
The statistical significance of differences between the 
pairs of treatment groups’ tumor incidence and incidence of 
lymph node metastasis were calculated using the Fisher’s exact 
test. The statistical significance of differences between pairs of 
treatment groups in tumor incidence, tumor weight, and tumor 
volume was calculated using the unpaired Student’s t test. The 
Kaplan–Meier method was used to estimate the differences 
in survival of control and treated groups of mice. Cumulative 
survival between the groups was compared using the log-rank 
test. A p value less than 0.05 was considered significant.
RESULTS
Tumor Growth and Metastasis after 
Intrapulmonary Injection
The incidence of tumor growth and metastasis found in 
the groups of mice after intrapulmonary injection of human 
SCLC cells are shown in Table 1. The rate of tumor develop-
ment was similar in all three groups of mice. Intrapulmonary 
implantation of human SCLC cells induced a local growth of 
the primary tumor at the injection site in the left lung with 
subsequent metastasis to the mediastinal and axillary lymph 
nodes, chest wall, and contralateral lung (Fig. 1). We found 
solitary microscopic nodules surrounded by normal lung 
developing 10 days after intrapulmonary injection of N417Lu 
or H187Lu SCLC cells (Fig. 1A) and 20 days after injection 
of H69ALu SCLC cells. Tumor size increased with time, with 
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macroscopic orthotopic lung tumors found 20 (N417Lu and 
H187Lu) or 30 days (H69ALu) after intrapulmonary injection 
(Fig. 1B). N417Lu and H187Lu tumors reached 100 mm3 in 
the left lung 30 days after injection, whereas H69ALu tumors 
reached a volume of 100 mm3 50 days after injection.
The entire procedure for intrapulmonary injection 
required approximately 2 minutes for each mouse and opera-
tive mortality was less than 5%. Mortality was mainly caused 
by pulmonary bleeding after injection. Mice with large 
tumors (> 200 mm3 in volume) had significantly more medi-
astinal lymph node metastasis than those with smaller tumors 
(< 50 mm3) in all three cell lines. Mice with large tumors 
also had more axillary lymph node and chest wall metasta-
sis than those with small tumors. The mice were killed when 
they became moribund from respiratory failure caused by the 
enlargement of mediastinal lymph nodes. The median duration 
of mouse survival was 16 weeks in the H69ALu group, 8 weeks 
in the H187Lu group, and 7 weeks in the N417Lu group.
To better monitor the progression and metastasis of 
human SCLC after implantation into the left lung, we estab-
lished stable GFP-expressing cells. Fifteen days after injection, 
all the mice developed small nodules in the injected lung iden-
tifiable by fluorescence microscopy (Fig. 2A). One of the three 
mice in each group had mediastinal lymph node metastasis 
(Fig. 2B). Fifty days after injection, all the mice had microme-
tastasis in the contralateral lung, axillary lymph node (Fig. 3C), 
FIGURE 1.  Tumor growth and metastasis after intrapulmo-
nary injection of N417Lu cells. A, Histopathologic findings of 
a pulmonary nodule. Solitary nodules surrounded by normal 
lung developed 10 days after injection of tumor cells; tumor 
size increased with time. B, Macroscopic findings of ortho-
topic lung tumor on day 20 after intrapulmonary implan-
tation. C, Histopathologic findings of contralateral lung 
metastasis on day 50 after intrapulmonary implantation. D, 
Macroscopic findings of lung tumor (arrow) and mediastinal 
lymph node (arrowhead) on day 50.
TABLE 1.  Growth Characteristics of Orthotopic Lung Tumor
Cell Line No. of Mice Tumor Incidence
No. of Metasases
Survival Median (range, wk)Mediastinal Lymph Node Axillary Lymph Node Chest Wall Lung
H69ALu 20 18   8 1 3 4 16 (12–20)
H187Lu 20 19 10 3 3 4 8 (6–10)
N417Lu 20 20  9 4 4 3 7 (6–8)
FIGURE 2.  Direct macroscopic view of GFP-transfected 
human small-cell lung cancer (SCLC) cells with orthotopic 
tumor and micrometastasis. A, Direct image of ortho-
topic human SCLC cells (H187Lu) 15 days after injection. 
B, Micrometastasis in the mediastinal (paraesophageal) 
lymph node 15 days after injection. C, micrometastasis in 
the right axillary lymph node 50 days after injection. D, 
Micrometastasis in the liver 50 days after injection.
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bone (rib and nasal), adrenal gland, or liver (Fig. 3D). We did 
not detect brain micrometastasis in any of the mice.
Comparison of Tumor Growth 
in the Lung In Vivo
Five mice per group were orthotopically implanted with 
human SCLC cells as described in Materials and Methods. 
The mean (±standard error) tumor volumes (mm3) in the 
N417Lu group were 94 ± 37 after 30 days and 920 ± 130 after 
50 days; in the H187Lu group, the means were 35 ± 1 after 30 
days and 588 ± 108 after 50 days. In the H69ALu group, the 
mean tumor volume (mm3) after 50 days was 12 ± 5 and after 
120 days was 593 ± 124 (Fig. 3). Thus, we found faster growth 
in the lung of N417Lu- and H187Lu-transplanted mice than in 
H69ALu-transplanted mice (p < 0.01).
Comparison of Tumor Growth in 
the Lung with Subcutis In Vivo
We injected 1.5 × 106 cells to the subcutis of the left flank 
with same condition as intrapulmonary injection. Five mice 
per group were orthotopically or subcutaneously implanted 
human SCLC cells as described in materials and methods. 
The mean (± standard error) subcutaneous growing tumor 
volume (mm3) injected after 30 days was 501 ± 157; 160 ± 83, 
after 50 days was 1764 ± 751 and 1167 ± 444 in N417Lu and 
H187Lu, respectively. In H69ALu, subcutaneous growing 
tumor volume (mm3) injected after 50 days was 225 ± 61, after 
120 days was 834 ± 448. The subcutis growth kinetics were 
faster in N417Lu or H187Lu than H69ALu cells (p < 0.01). 
The deviation of volume in orthotopically growing tumor is 
significantly lower than subcutaneously tumor (p < 0.01).
In Vitro Sensitivity of SCLC Cells 
to Various Antitumor Agents
We tested the cytotoxic effects of four different 
anticancer agents in all three human SCLC cell lines using 
72-hour continuous drug exposure. The IC
50
 values are 
summarized in Table 2. The sensitivity (mean IC
50
 value) to 
SN-38, the active metabolite of irinotecan, was five to six times 
higher in N417Lu cells (0.05 μM) than in H187Lu (0.27 μM) 
and H69ALu cells (0.31 μM). The sensitivity to paclitaxel was 
11 to 17 times higher in N417Lu (6.5 μM) and H187Lu cells 
(4.3 μM) than in H69ALu cells (75.0 μM). The sensitivity to 
cisplatin was five times higher in the H69ALu group (4.7 μM) 
than in either the N417Lu (24.0 μM) or H187Lu group (25.7 
μM). The sensitivity to etoposide was three times higher in the 
N417Lu (22.0 μM) and H187Lu groups (28.5 μM) than in the 
H69ALu group (72.5 μM).
Antitumor Effects of Various Treatments 
on Orthotopic Human SCLC Tumors
To compare the efficacy of different chemotherapeutic 
agents in each of our tumor models, groups of mice (n = 5) 
were randomized to weekly intraperitoneal treatment with 
saline (control), 6 mg/kg of cisplatin, 50 mg/kg of paclitaxel, 
125 mg/kg of irinotecan, or 40 mg/kg of etoposide. Therapy 
was initiated on day 10 (H187Lu and N417Lu) or day 20 
(H69ALu) after tumor injection, coincident with the forma-
tion of microscopic lesions. Mice were killed after 5 (H187Lu 
and N417Lu) or 7 (H69ALu) weeks of therapy. Tumor bur-
den was assessed by lung and tumor weight (mg) and primary 
tumor volume (mm3) (Table 3). Irinotecan (Fig. 4B, 4G ) sig-
nificantly inhibited the growth and progression of tumors in all 
three tested human SCLC models over the control (Fig. 4A,F). 
Paclitaxel significantly inhibited the growth and progression 
of N417Lu and H69ALu tumors over the control (Fig. 4C, H), 
and cisplatin and etoposide significantly inhibited the growth 
and progression of H69ALu tumors over the control (Fig. 4 
D, E, I, J). Furthermore, in a survival experiment using the 
N417Lu orthotopic model, weekly treatment with irinotecan 
significantly improved overall survival in comparison with the 
vehicle treated control group (Fig. 5 ).Therapy was well toler-
ated and mice experienced no loss of body weight or diarrhea.
DISCUSSION
In the present study, we used our previously described 
method to grow human lung cancer cell lines orthotopically 
in nude mice13–15 to establish three human SCLC models. 
In addition, we characterized the biological status, clinical 
course, and sensitivity against different chemotherapy drug 
in these models. To our knowledge, only one group had cre-
ated an orthotopic model of human SCLC previously, using 
severe combined immunodeficient mice because their nude 
FIGURE 3.  In vivo growth curve of N417Lu (■), H187Lu (▲), 
and H69ALu (● ) cell lines injected into the left lung. Five mice 
per group were orthotopically implanted with human small-
cell lung cancer cells as described in Materials and Methods. 
Vertical bars represent the standard error of the mean. Note 
that N417Lu and H187Lu cell lines had a faster growth rate 
than the H69ALu cell line (p < 0.01).
TABLE 2.  In Vitro Sensitivity of Small-Cell Lung Cancer Cells 
against Various Antitumor Agents
Therapy N417Lu H187Lu H69ALu
SN-38 (μM) 0.05 ± 0.02 0.27 ± 0.11 0.31 ± 0.07
Paclitaxel (μM) 6.5 ± 1.8 4.3 ± 1.1 75.0 ± 25.0
CDDP (μM) 24.0 ± 6.7 25.7 ± 9.8 4.7 ± 0.6
VP-16 (VM) 22.0 ± 14.0 28.5 ± 21.5 72.5 ± 3.5
Results depicted represent a mean ± standard deviation of three experiments.SN-38, 
7-ethyl-10-hydroxycamptothecin; CDDP, cis-diamminedichloro-platinum; VP-16, etoposide.
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mice were not amenable to orthotopic reconstitution.16 The 
orthotopic models may become the investigation of clinically 
relevant strategies and new therapies against metastatic SCLC 
in nude mice.
Our study had several major findings. First, we estab-
lished three different orthotopic tumor models from human 
SCLC cell lines in nude mouse models. For each model, tumors 
started as a solitary mass in the left lung and then spread to the 
mediastinal and axillary lymph nodes, chest wall, and right 
lung until the mice became moribund from respiratory fail-
ure, mimicking the course of human SCLC seen in the clinic. 
The gross pathologic features of SCLC are rarely examined 
in detail because the majority of patients with SCLC do not 
undergo surgical resection. Therefore, most of the macro-
scopic findings in these tumors come from autopsies, where 
the appearance of the tumors may be altered from therapy.17 
Using these murine models, we can evaluate not only the pri-
mary SCLC tumor but also the lymphatic and distant metasta-
ses. Although subcutaneous xenograft models have been used 
widely to evaluate the antitumor activity of new compounds, 
those models present a major disadvantage because the tumor 
cells do not metastasize. In addition, the orthotopic implanta-
tion of tumor cells better mimics the tumor–host interactions 
seen in human disease, which do not manifest when tumors 
are implanted ectopically.18,19
Second, our models had low (<5%) implantation mor-
tality rates, mainly caused by pulmonary bleeding after 
injection, and were quite simple to replicate. It took only 
approximately 2 hours to implant the cell suspension into 50 
nude mice. Although we cannot measure the size of a grow-
ing tumor in the lung without killing the animal, the standard 
deviations among tumor volumes in orthotopic tumors in our 
murine model were significantly lower than those of the sub-
cutaneous tumors in all three cell lines (p < 0.01), highlighting 
the reproducibility of the model.
Third, to detect disease at the single-cell level in 
human SCLC, we established stable GFP-expressing cells. 
A limitation of our study is that the mice did not die from 
FIGURE 4.  Antitumor effects of 
irinotecan, paclitaxel, cisplatin, and 
etoposide as single agents admin-
istrated to mice bearing orthotopic 
lung tumors. A–E, cross-sectional 
gross images of an H69ALu tumor 
treated with vehicle, irinotecan, 
paclitaxel, cisplatin, or etoposide. F–J, 
macroscopic findings of an H69ALu 
tumor treated with vehicle, irinote-
can, paclitaxel, cisplatin, or etopo-
side. Arrows indicate tumor borders.
TABLE 3.  Antitumor Effects of Various Treatments on Orthotopic Human Small-Cell Lung Cancer Tumor
Therapy Incidence Total Lung Weight (mg) Tumor Volume (mm3) Mediastinal Lymph Nodea
N417Lu Control 15/15 924 ± 163b 498 ± 114 15
CPT-11 10/15 256 ± 15d
Paclitaxel 15/15 412 ± 163c 162 ± 81 21 ± 14d
CDDP 8/8 711 ± 195 266 ± 118 8
VP-16 8/8 555 ± 187 217 ± 100 8
H187Lu Control 10/10 670 ± 126 736 ± 167 10
CPT-11 9/10 342 ± 43d 57 ± 41d 3c
Paclitaxel 8/8 445 ± 114 150 ± 95 6
CDDP 8/8 508 ± 102 202 ± 104 7
VP-16 8/8 652 ± 123 253 ± 190 7
H69ALu Control 10/10 524 ± 102 250 ± 112 10
CPT-11 8/10 257 ± 9c 13 ± 9c 3c
Paclitaxel 7/10 290 ± 76c 22 ± 18c 2c
CDDP 6/10 245 ± 9c 2 ± 1c 1c
VP-16 8/10 236 ± 6c 8 ± 7c 1c
aMediastinal lymph node metastasis.
bMean ± standard error.
cp < 0.01.
dp < 0.001.
CDDP, cis-diamminedichloro-platinum; CPT, irinotecan; VP-16, etoposide.
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distant organ metastases, such as to the contralateral lung, 
liver, bone, and brain, as is usually seen in the clinical course 
of human SCLC. However, our imaging analysis highlighted 
micrometastasis in the contralateral lung, lymph nodes, 
and liver at the time the mice became moribund. Imaging 
metastasis in mice using tumor cells expressing GFP presents 
the possibility for new insights into real-time tumor growth.20 
The very bright GFP fluorescence enables orthotopic tumor 
and metastases to be externally observed in the organs, 
including the lymph nodes, liver, adrenal gland, and brain. No 
contrast agents or radioactive materials were needed.
Finally, we evaluated all three orthotopic SCLC models 
in vitro and in vivo for the antitumor effects of irinotecan, cis-
platin, paclitaxel, and etoposide, which are used widely for the 
treatment of SCLC. Although in vitro results correlated with 
in vivo results for irinotecan and cisplatin in all three human 
SCLC cell lines, this correlation was not observed for pacli-
taxel and etoposide. Because it is not appropriate to speculate 
on the clinical effects of novel therapies on the basis of in vitro 
experimental results alone, as the mechanisms by which the 
drugs interact in vivo is not clear and experimental conditions 
in vitro differ markedly from those in vivo, there is a clear need 
for effective animal models, which mimics the human disease 
as close as possible.
Importantly, the close correlation between clinical 
results and those obtained in our experimental models indi-
cates that the results of murine studies could be predictive of 
results in the clinical setting.21 In conclusion, our development 
of a reliable, reproducible, simple, orthotopic murine model of 
human SCLC provides a means for a better understanding 
of the biology of this disease and will enable better evaluation 
of novel therapeutic strategies.
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FIGURE 5.  Therapeutic effects of irinotecan in the N417Lu 
orthotopic lung tumor model. Mice were injected intraperito-
neally with 15-mg/kg irinotecan on days 14, 21, 28, 35, 42, 
and 49 after the implantation of 1.5 × 106 N417Lu tumor 
cells into the left lung. Irinotecan significantly improved 
survival over control (p = 0.018). The survival data was com-
pared using the log-rank test. 
